Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 3, 2004, Pages 487-491

  Koopmann, Jens ^a   Fedarko, Neal S ^b   Jain, Alka ^b   Maitra, Anirban ^a   Iacobuzio Donahue, Christine ^a   Rahman, Ayman ^a   Hruban, Ralph H ^a   Yeo, Charles J ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; OSTEOPONTIN; TUMOR MARKER; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EVALUATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; ADENOCARCINOMA; BIOSYNTHESIS; CASE CONTROL STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; MACROPHAGE; MALE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION; MACROPHAGES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442635516     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology, 1999;117:1464-84.
2. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV. Pancreaticoduodenectomy for cancer of the head of the pancreas:201 patients. Ann Surg, 1995;221:721-31.
3. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am, 2002;16:37-52.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg, 2000;4:567-79.
5. Tersmette AC, Petersen GM, Offerhaus GJA, et al. Increased risk of pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res, 2001;7:738-44.
6. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med, 1999;131:247-55.
7. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res, 2002; 62:3789-93.
8. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 2000;119:1447-53.
9. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol, 2002;160:1239-49.
10. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res, 2002;62:819-926.
11. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol, 2003;162:1151-62.
12. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res, 2002;62:2890-6.
13. Zhou W, Sokoll LJ, Bruzek DJ, et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers & Prev, 1998;7:109-12.
14. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Histochem J, 1999;31:433-41.
15. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-β-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer, 2001;93:204-11.
16. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol, 2001;159:837-43.
17. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma. Am J Pathol, 2002;160:91-9.
18. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 2001;7:4060-6.
19. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 2002;287:1671-9.
20. O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb, 1994;14:1648-56.
21. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 1996;271:509-12.
22. Bayless KJ, Davis GE. Identification of dual α4β1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol Chem, 2001;276:13483-9.
23. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer, 2000;83:156-63.
24. Fedarko NS, Jain A, Karadag A, Fisher LW. SIBLING interactions with complement factor H and pro-matrixmetalloproteinases. In: Third International Conference on Osteopontin and SIBLING proteins. San Antonio, TX; 2002.
25. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int, 1999;56:571-80.
26. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem, 2000;275:16666-72.
27. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 1996;13:97-104.
28. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res, 1999;5:2271-7.
29. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res, 2002;62:3417-27.
30. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer, 2002;95:506-12.
31. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst, 2002;94:513-21.
32. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol, 1994;145:610-23.
33. Nakamura M, Oka M, Iizuka N, et al. Osteopontin expression in chronic pancreatitis. Pancreas, 2002;25:182-7.
34. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res, 2002;62:1868-75.
35. Cerwenka H, Aigner R, Bacher H, et al. Pancreatitis-associated protein (PAP) in patients with pancreatic cancer. Anticancer Res, 2001;21:1471-4.
36. Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys, 1999;44:1039-46.